Seer (NASDAQ:SEER) Issues Quarterly Earnings Results

Seer (NASDAQ:SEER) posted its quarterly earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03, FiscalAI reports. The business had revenue of $4.20 million during the quarter, compared to analyst estimates of $4.60 million. Seer had a negative net margin of 484.51% and a negative return on equity of 25.88%.

Here are the key takeaways from Seer’s conference call:

• Q4 revenue was $4.2M and full‑year 2025 revenue was $16.6M (17% YoY) but missed expectations due to customer budget pressures and delayed NIH funding; guidance for 2026 is $16–$18M, reflecting limited near‑term growth visibility.
• Commercial momentum — installed base grew 67% to 82 instruments, consumable kit volume rose ~69%, total revenue excluding related‑party sales grew ~33%, and the Proteograph was selected for multiple population‑scale studies (including 20k and 10k sample projects) while cumulative publications nearly doubled to 70.
• Product roadmap and innovation — launched the Proteograph ONE assay and SP200 automation, plans to release PAS v4 with an LLM chat interface later this year, is developing a proteoform profiling assay for 2027, and expects next‑generation detector/platform data in H2 2026.
• Strong financial runway and shareholder returns — ended the year with ~$241M cash and investments, improved free‑cash‑flow loss to ~$45.6M, believes it has capital to reach breakeven, repurchased ~11.7M shares and the board authorized an additional $25M repurchase, and adopted a plan to preserve ~$262M of NOL tax assets.

Seer Price Performance

Shares of Seer stock traded down $0.01 on Thursday, hitting $2.08. The company had a trading volume of 673,128 shares, compared to its average volume of 256,985. The firm has a market capitalization of $116.04 million, a P/E ratio of -1.53 and a beta of 1.63. Seer has a twelve month low of $1.62 and a twelve month high of $2.41. The stock has a 50-day moving average of $1.89 and a 200-day moving average of $2.02.

Institutional Investors Weigh In On Seer

Several hedge funds have recently bought and sold shares of SEER. Vanguard Group Inc. increased its position in Seer by 0.9% during the third quarter. Vanguard Group Inc. now owns 2,221,404 shares of the company’s stock worth $4,820,000 after acquiring an additional 18,760 shares during the period. Bridgeway Capital Management LLC lifted its stake in Seer by 15.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 837,443 shares of the company’s stock valued at $1,792,000 after purchasing an additional 112,100 shares during the last quarter. Geode Capital Management LLC raised its position in Seer by 16.5% in the second quarter. Geode Capital Management LLC now owns 509,727 shares of the company’s stock valued at $1,091,000 after purchasing an additional 72,265 shares during the last quarter. Jane Street Group LLC boosted its position in Seer by 33.3% during the 1st quarter. Jane Street Group LLC now owns 254,174 shares of the company’s stock worth $430,000 after buying an additional 63,432 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Seer by 2.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 235,485 shares of the company’s stock worth $431,000 after purchasing an additional 6,304 shares during the last quarter. 75.20% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Seer in a report on Thursday, January 22nd. Wall Street Zen raised shares of Seer to a “hold” rating in a research note on Saturday, December 13th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.